Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
I332490-100mg | 100mg | In stock | $1,018.90 | |
I332490-250mg | 250mg | In stock | $2,292.90 | |
I332490-1g | 1g | In stock | $8,253.90 | |
I332490-5g | 5g | In stock | $37,142.90 |
a proton pump inhibitor (PPI)
Synonyms | s3666 | CS-6444 | ILAPRAZOLE [WHO-DD] | DTXSID10870115 | 2-[(4-methoxy-3-methyl-pyridin-2-yl)methylsulfinyl]-6-pyrrol-1-yl-1h-benzoimidazole | GTPL10512 | 1H-Benzimidazole,2-[[(4-methoxy-3-methyl-2-pyridinyl)methyl]sulfinyl]-5-(1H-pyrrol-1-yl)- (9CI) | Il |
---|---|
Specifications & Purity | Moligand™, ≥98% |
Biochemical and Physiological Mechanisms | Ilaprazole is a proton pump inhibitor (H+/K+ ATPase inhibitor) that suppresses acids secretion. Ilaprazole is a potent and selective inhibitor of T-cell-originated protein kinase (TOPK) that suppresses cancer growth. |
Storage Temp | Store at -20°C |
Shipped In | Ice chest + Ice pads |
Grade | Moligand™ |
Action Type | INHIBITOR |
Mechanism of action | Potassium-transporting ATPase inhibitor |
ALogP | 2.3 |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
IUPAC Name | 2-[(4-methoxy-3-methylpyridin-2-yl)methylsulfinyl]-6-pyrrol-1-yl-1H-benzimidazole |
---|---|
INCHI | InChI=1S/C19H18N4O2S/c1-13-17(20-8-7-18(13)25-2)12-26(24)19-21-15-6-5-14(11-16(15)22-19)23-9-3-4-10-23/h3-11H,12H2,1-2H3,(H,21,22) |
InChi Key | HRRXCXABAPSOCP-UHFFFAOYSA-N |
Canonical SMILES | CC1=C(C=CN=C1CS(=O)C2=NC3=C(N2)C=C(C=C3)N4C=CC=C4)OC |
Isomeric SMILES | CC1=C(C=CN=C1CS(=O)C2=NC3=C(N2)C=C(C=C3)N4C=CC=C4)OC |
PubChem CID | 214351 |
Molecular Weight | 366.44 |
PubChem CID | 214351 |
---|---|
CAS Registry No. | 172152-36-2 |
DrugBank Ligand | DB11964 |
DrugCentral Ligand | 3961 |
Enter Lot Number to search for COA:
Find and download the COA for your product by matching the lot number on the packaging.
Lot Number | Certificate Type | Date | Item |
---|---|---|---|
K2221015 | Certificate of Analysis | Sep 15, 2022 | I332490 |
K2221047 | Certificate of Analysis | Sep 15, 2022 | I332490 |
K2221053 | Certificate of Analysis | Sep 15, 2022 | I332490 |
K2221054 | Certificate of Analysis | Sep 15, 2022 | I332490 |
Refractive Index | n20D1.71 (Predicted) |
---|---|
Boil Point(°C) | ~651.0° C at 760 mmHg (Predicted) |
Melt Point(°C) | 271.46° C (Predicted) |
Starting at $241.90
Starting at $385.90
Starting at $69.90
1. Kwon D, Chae JB, Park CW, Kim YS, Lee SM, Kim EJ, Huh IH, Kim DY, Cho KD. (2001) Effects of IY-81149, a newly developed proton pump inhibitor, on gastric acid secretion in vitro and in vivo.. Arzneimittelforschung, 51 (3): (204-13). [PMID:11304936] [10.1021/op500134e] |
2. Zhou G, Shi S, Zhang W, Tan Z, Chen Y, Guo D, Zhou H, Hu H, Tan J. (2010) Identification of ilaprazole metabolites in human urine by HPLC-ESI-MS/MS and HPLC-NMR experiments.. Biomed Chromatogr, 24 (10): (1130-5). [PMID:20352613] [10.1021/op500134e] |
3. Wang L, Zhou L, Hu H, Lin S, Xia J. (2012) Ilaprazole for the treatment of duodenal ulcer: a randomized, double-blind and controlled phase III trial.. Curr Med Res Opin, 28 (1): (101-9). [PMID:22070512] [10.1021/op500134e] |
4. Ji XQ, Du JF, Chen G, Chen G, Yu B. (2014) Efficacy of ilaprazole in the treatment of duodenal ulcers: a meta-analysis.. World J Gastroenterol, 20 (17): (5119-23). [PMID:24803828] [10.1021/op500134e] |
5. Pu J, Wang F, Tang W, Zhu M. (2018) Biotransformation of Ilaprazole in Human Liver Microsomes and Human: Role of CYP3A4 in Ilaprazole Clearance and Drug-Drug Interaction.. Drug Metab Dispos, 46 (10): (1453-1461). [PMID:30002078] [10.1021/op500134e] |